ANAGRELIDE HYDROCHLORIDE MONOHYDRATE, PEGINTERFERON ALFA-2A, MK-3543, BUSULFAN, MK-3543, RUXOLITINIB, MK-3543, MK-3543, RUXOLITINIB, PEGINTERFERON ALFA-2A
MK-3543-006
Phase 3 small_molecule active
Quick answer
ANAGRELIDE HYDROCHLORIDE MONOHYDRATE, PEGINTERFERON ALFA-2A, MK-3543, BUSULFAN, MK-3543, RUXOLITINIB, MK-3543, MK-3543, RUXOLITINIB, PEGINTERFERON ALFA-2A for Essential Thrombocythemia patients who have an inadequate response to or are intolerant of hydroxyurea is a Phase 3 program (small_molecule) at Merck Sharp and Dohme with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Merck Sharp and Dohme
- Indication
- Essential Thrombocythemia patients who have an inadequate response to or are intolerant of hydroxyurea
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active